19/03/2017 GloboMailPro::1selecteditem:12950867PubMed

Assunto 1selecteditem:12950867PubMed
De SentbyNCBI<nobody@ncbi.nlm.nih.gov>
Para <knapp.colih@globo.com>
Data 19/03/201710:35

ThismessagecontainssearchresultsfromtheNationalCenterforBiotechnologyInformation(NCBI)atthe
U.S.NationalLibraryofMedicine(NLM).Donotreplydirectlytothismessage

Senton:SunMar1909:30:562017

1selecteditem:12950867

PubMedResults
Item1of1(DisplaythecitationinPubMed)

1. PaediatrAnaesth.2003Sep13(7):6336.

UseoferythropoietinforbloodlesssurgeryinaJehovah'switness
infant.
PrezFerrerA1,DeVicenteJ,GredillaE,GarcaVegaMI,BourgeoisP,GoldmanLJ.

Authorinformation:

1
TheDepartmentofPaediatricAnaesthesiology,LaPazChildren'sUniversityHospital,Madrid,
Spain.a.perezf@teleline.es

Abstract

Wepresentacaseofsurgeryina2montholdinfantoftheJehovah'sWitness(JW)faithweighing2.8kg
scheduledforleftupperlobectomybecauseofcongenitallobaremphysema.Hepresentedwith
physiologicalanaemia(haematocrit33.8%)inaccordancewithhisage.Becauseoftherelativeemergency
ofsurgery,ashorterythropoietincoursewasinstituted.Recombinanthumanerythropoietin(rHuEPO)ata
dosageof180Uxkg1xday1wasadministeredfor10dayspreoperativelyandfor4days
postoperatively.Ironwasadministeredorallyandintravenouslyovertheentireperioperativeperiod.No
sideeffectsfromeithererythropoietinorintravenouslyadministeredironwereobserved.Toour
knowledge,thisisthefirstcasepublishedofashortperioperativerHuEPOcourseinaninfant.

PMID:12950867[IndexedforMEDLINE]

https://mail.globo.com/webmail/?_task=mail&_action=print&_uid=5&_mbox=INBOX&_safe=1&_extwin=1 1/1